Deals In Depth: April 2019
Alnylam and Regeneron will work on RNAi therapies for ocular, CNS, and liver disease indications in a $1.15bn alliance. Novartis paid $310m up front for IFM Tre, which focuses on abnormal NLRP3 inflammasome activation. Biopharma financing was down in April compared with the previous month, but device funding increased.
You may also be interested in...
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.